RemeGen Co., Ltd. (HKG:9995)
Hong Kong · Delayed Price · Currency is HKD 88.80
+2.60 (3.02%)
At close: Mar 13, 2026
RemeGen Market Cap
RemeGen has a market cap or net worth of 63.05 billion as of March 13, 2026. Its market cap has increased by 353.96% in one year.
Market Cap
63.05B
Enterprise Value
64.17B
Revenue
3.62B
Ranking
n/a
PE Ratio
61.86
Stock Price
88.80
Market Cap Chart
Since November 9, 2020, RemeGen's market cap has increased from 33.39B to 63.05B, an increase of 88.84%. That is a compound annual growth rate of 12.64%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 13, 2026 | 63.05B | 39.50% |
| Dec 31, 2025 | 45.20B | 222.75% |
| Dec 31, 2024 | 14.00B | -55.02% |
| Dec 29, 2023 | 31.13B | -25.43% |
| Dec 30, 2022 | 41.75B | 9.42% |
| Dec 31, 2021 | 38.16B | -18.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Nov 9, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| WuXi Biologics | 142.83B |
| Innovent Biologics | 140.29B |
| Sino Biopharmaceutical | 107.80B |
| Akeso | 102.34B |
| Sichuan Kelun-Biotech Biopharmaceutical | 92.06B |
| 3SBio | 52.10B |
| Shanghai Henlius Biotech | 36.77B |
| Biocytogen Pharmaceuticals (Beijing) | 35.97B |